Inventiva Shares Surge as Investors Bet on Liver Disease Treatment Market

Biotech company Inventiva's stock surged 50% in early 2026, highlighting investor optimism over its liver disease drug lanifibranor. The treatment market for liver disease MASH is expected to reach $24 billion by the next decade. Positive Phase 3 data for lanifibranor due in H2 2026 could pave the way for commercialization and boost revenues. Big Pharma interest in MASH is evident, with recent acquisitions and partnerships. Analysts see a "value-inflecting catalyst" ahead and rate the stock "buy" or "strong buy."